Robert B. Naso
Keine laufenden Positionen mehr
Profil
Robert B.
Naso has been an Executive Vice President of Research and Development for Affymax, Inc. since 2004.
From 1995 to 2004, he was Senior Vice President of Research and Development for Nabi Biopharmaceuticals and Vice President of Research and Vice President of Research and Development for Univax Biologics, Inc. from 1992 to 1995.
From 1983 to 1992, Dr. Naso held various positions at Johnson & Johnson, including Director of Bioscience at the R.W.
Johnson Pharmaceutical Research Institute.
He was a Faculty Member of The University of Texas and Managing Director of the Anderson Hospital and Tumor Institute from 1973 to 1983.
Dr. Naso received a PhD from West Virginia University and a BA degree from the State University of New York.
Ehemalige bekannte Positionen von Robert B. Naso
| Unternehmen | Position | Ende |
|---|---|---|
| AFFYMAX, INC. | Technik-/Wissenschafts-/F&E-Leiter | 31.12.2007 |
Univax Biologics, Inc.
 Univax Biologics, Inc. BiotechnologyHealth Technology Univax Biologics, Inc. developed and manufactured anti-infective products. The firm developed different products that prevented and treated infectious diseases and related complications through activation targeting of human immune system. Its products included vaccines for long-term protection, specific polyclonal antibodies for short-term protection and therapeutic intervention. The company was founded in 1988 and was located in Rockville, MD. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1995 |
| R.W. Johnson Pharmaceutical Research Institute | Corporate Officer/Principal | 01.01.1992 |
Nabi Biopharmaceuticals
 Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Robert B. Naso
| West Virginia University | Doctorate Degree |
| State University of New York at Buffalo | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AFFYMAX, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | Health Technology |
Univax Biologics, Inc.
Univax Biologics, Inc. BiotechnologyHealth Technology Univax Biologics, Inc. developed and manufactured anti-infective products. The firm developed different products that prevented and treated infectious diseases and related complications through activation targeting of human immune system. Its products included vaccines for long-term protection, specific polyclonal antibodies for short-term protection and therapeutic intervention. The company was founded in 1988 and was located in Rockville, MD. | Health Technology |
| R.W. Johnson Pharmaceutical Research Institute |
